Hanaco Venture Capital

Hanaco Venture Capital is a Tel Aviv generalist fund with a substantial healthtech sub-thesis, backing Israeli founders building applied-AI software for clinical workflows and healthcare platforms. Hanaco operates across the early-to-growth continuum, which means the firm can lead a Series A, follow on through Series B, and stay engaged into growth rounds when a portfolio company is performing.

The healthtech thesis is concentrated on software-first companies that use applied AI to disrupt clinical workflows, ambulatory care delivery, and the administrative and clinical software stack. Hanaco does not publish a healthcare-specific portfolio carve-out, but the firm’s broader investment style favors capital-efficient software businesses with strong founding teams and clear United States commercial ambition. For physician founders, that means the conversation will quickly move past the clinical pitch and into questions about distribution, sales motion, retention, and the path to a defensible category-leader position.

Check sizes run from 1 million to 5 million dollars at entry, which positions Hanaco comfortably as a seed or Series A lead with capacity to follow on. Stage coverage spans seed through growth, an unusually wide aperture that is useful for founders who want a long-term capital partner rather than a one-round investor. Geography is Israel-anchored but the fund expects portfolio companies to scale into the United States, and the partner team spends real time on the ground there.

The team is not deeply published, but Hanaco operates with a small partner group that takes lead-investor responsibility seriously and engages in hands-on portfolio support, particularly around United States go-to-market. Diligence is fast when conviction is high.

Approach Hanaco when you are an Israeli or Israeli-adjacent founder with a software product in market, early customer or pilot revenue, and a credible United States expansion thesis. Pure pre-seed founders with only a deck will struggle; the firm wants to see product, team, and at least an early commercial signal. Warm introductions from Tel Aviv operators, other Israeli VCs, or United States health-system executives who know the partner team are the most reliable path in. Avoid pitching deep-tech device or therapeutics plays; Hanaco’s strength is software, not hardware or molecules. Time the outreach when you are six to nine months from a meaningful round, have customer references ready, and can articulate the wedge into the United States in operational rather than aspirational terms.